SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Jack London Synthetic CCD — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientJack London
Date of birth1876-01-12
IdentifiersMRN HR-ET010-SYN-TD; SSN (made up) 000-10-4482
Document date2026-11-01
AuthorEleanor Whitcombe-Ibe, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Establishing care for tiredness and ankle swelling, with high blood pressure and abnormal kidney tests, and heavy drinking found at the visit: kidney, liver and alcohol tests, AUDIT and DSM-5-TR assessment, withdrawal planning, mood and safety, his writing schedule, and a nephrology consultation. Concerns: Tired by afternoon, with swollen ankles, and frightened by the word 'kidneys' again; He knows the drinking is hurting him and wants to stop without losing his work; He wants to keep writing a thousand words every morning. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Naproxen 500 mg oral tablet twice daily, bought over the counter at full strength and taken most days for about two years for knee and back pain; stopped at intakeOne tablet by mouth twice a day, self-directedOral route1913-08-01 to 1915-08-04stoppedS
Losartan 50 mg oral tablet once dailyOne tablet by mouth every morningOral route1915-08-04 to 1915-09-15completedS
Losartan 100 mg oral tablet once dailyOne tablet by mouth every morningOral route1915-09-15activeS
Chlordiazepoxide 25 mg oral capsule, fixed five-day taper for alcohol withdrawal (four capsules on day 1, three on day 2, two on day 3, one on days 4 and 5), dispensed for five days only, with a daily telephone checkUp to one capsule four times a day on day 1, tapering to one a day by day 4; stop after day 5; no alcohol or drivingOral route1915-08-04 to 1915-08-08completedS
Thiamine 100 mg oral tablet once dailyOne tablet by mouth dailyOral route1915-08-04activeS
Acetaminophen 500 mg oral tablet, one or two tablets up to four times a day as needed for pain, no more than 2,000 mg in a day, in place of naproxenOne to two tablets by mouth every six hours as needed; no more than four tablets a dayOral route1915-08-04activeS
Naltrexone 50 mg oral tablet once daily, with a wallet card warning that it blocks opioid pain medicinesOne tablet by mouth every morningOral route1915-08-18activeS
Vitamin D3 (cholecalciferol) 25 micrograms (1,000 units) oral tablet once dailyOne tablet by mouth dailyOral route1915-09-15activeS
Dapagliflozin 10 mg oral tablet once daily, held on any day he cannot eat or drink normally, and before surgeryOne tablet by mouth every morning; sick-day rules in writingOral route1915-10-13activeS
Diclofenac 1% gel, 4 g rubbed into the outer right ankle four times a day for up to seven days, in place of any oral anti-inflammatory medicineApply 4 g to the ankle four times a day for up to seven daysTopical route1915-09-01 to 1915-09-08completedS

Procedures

ProcedureDatesStatusEvidence
Ultrasound of the abdomen and kidneys: right kidney 10.8 cm and left 11.0 cm with increased cortical echogenicity and preserved cortical thickness, no stones, no hydronephrosis, no cysts; bright liver consistent with steatosis, smooth outline, normal spleen, no ascites1915-08-18 to 1915-08-18completedS
Vibration-controlled transient elastography of the liver: median liver stiffness 7.2 kPa (interquartile range under 30 percent), controlled attenuation parameter 312 dB/m; advanced fibrosis unlikely1915-08-18 to 1915-08-18completedS
Advance care planning conversation, about 20 minutes1915-09-29 to 1915-09-29completedS

Immunizations

DateVaccineStatusEvidence
1915-09-29Influenza vaccine, inactivated, trivalent, preservative-free, for this seasoncompletedS
1915-09-29Pneumococcal conjugate vaccine (PCV20), single dosecompletedS
1915-09-29Hepatitis B vaccine (HepB-CpG), first of two dosescompletedS
1915-09-29Hepatitis A vaccine, adult, first of two dosescompletedS
1915-10-27Hepatitis B vaccine (HepB-CpG), second of two dosescompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1897 to 1898Scurvy in the gold fields in his early twenties; recoveredD (CLM-0003)
1907 to 1909Skin sores, swollen and peeling hands and feet, and a silvery skin during a long Pacific voyage, with five weeks in hospital; the hands recovered and the skin cleared without treatment; the diagnoses were never settledR (CLM-0006, CLM-0007)
July 1913Appendectomy, at which kidney damage was foundD (CLM-0009)
1914Dysentery and joint pain (described as rheumatism) while working abroadD (CLM-0010)

Family History

No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.

Health Concerns

ConcernStatusEvidence
Tired by afternoon, with swollen ankles, and frightened by the word 'kidneys' againactiveS
He knows the drinking is hurting him and wants to stop without losing his workactiveS
He wants to keep writing a thousand words every morningactiveS

Assessment

Most recent measures: Sodium [Moles/volume] in Serum or Plasma 139 on 1915-10-27; Potassium [Moles/volume] in Serum or Plasma 4.7 on 1915-10-27; Carbon dioxide, total [Moles/volume] in Serum or Plasma 23 on 1915-10-27; Urea nitrogen [Mass/volume] in Serum or Plasma 24 on 1915-10-27; Creatinine [Mass/volume] in Serum or Plasma 2.13 on 1915-10-27; Glucose [Mass/volume] in Serum or Plasma 94 on 1915-08-04; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1910)/1.73 sq M 40 on 1915-10-27; Albumin/Creatinine [Mass Ratio] in Urine 96 on 1915-10-27; Urate [Mass/volume] in Serum or Plasma 8.4 on 1915-08-04; Calcium [Mass/volume] in Serum or Plasma 9.2 on 1915-08-04; Phosphate [Mass/volume] in Serum or Plasma 3.8 on 1915-08-04; Parathyrin.intact [Mass/volume] in Serum or Plasma 74 on 1915-08-04; Hemoglobin [Mass/volume] in Blood 13.6 on 1915-08-04; MCV [Entitic mean volume] in Red Blood Cells by Automated count 96 on 1915-10-27; Platelets [#/volume] in Blood by Automated count 182 on 1915-08-04; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 29 on 1915-10-27; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 26 on 1915-10-27; Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma 54 on 1915-10-27; Albumin [Mass/volume] in Serum or Plasma 4.1 on 1915-08-04; Bilirubin.total [Mass/volume] in Serum or Plasma 0.9 on 1915-08-04; INR in Platelet poor plasma by Coagulation assay 1 on 1915-08-04; Phosphatidylethanol [Mass/volume] in Blood 6 on 1915-10-27; Hemoglobin A1c/Hemoglobin.total in Blood 5.4 on 1915-08-04; Cholesterol [Mass/volume] in Serum or Plasma 214 on 1915-08-04; Cholesterol in HDL [Mass/volume] in Serum or Plasma 58 on 1915-08-04; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 128 on 1915-08-04; Triglyceride [Mass/volume] in Serum or Plasma 140 on 1915-08-04; Total score [AUDIT] 9 on 1915-10-27; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 on 1915-10-27; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 4 on 1915-10-27; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 24 on 1915-09-15; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 1915-09-29 [S]

Strengths and supports: engagement in care [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Tiredness, ankle swelling and high blood pressure (158/98 mmHg) with a raised creatinine (1.98 mg/dL, eGFR 43) and albumin in the urine (240 mg/g), found at intake; a creatinine of 1.7 mg/dL at an insurance examination about fourteen months ago, by his account; chronicity and cause under evaluation with a nephrology consultationresolvedconfirmed R94.4S — Synthetic presenting problem anchored to the documented kidney damage found in 1913; superseded when the consultation staged chronic kidney disease.
Chronic kidney disease, stage G3b A2 (eGFR 42 to 43, urine albumin 240 mg/g), most likely from hypertension with a contribution from two years of daily naproxen; kidneys of normal size, without stones or obstruction; urine sediment bland; synthetic modern diagnosis linked to his documented kidney diseaseactiveconfirmed N18.32S — Synthetic modern diagnosis made at the consultation, anchored to his documented kidney damage and death from uraemia; the cause in the modern episode is synthetic and is not a claim about his real kidneys.
Hypertensive chronic kidney disease, untreated until intakeactiveconfirmed I12.9S — Synthetic modern diagnosis made at the consultation.
Alcohol use disorder, severe (seven DSM-5-TR criteria): a bottle of whisky or more most days for years, a morning drink to steady his hands, failed attempts to cut down, and drinking despite knowing it harms his health; AUDIT 27; PEth 410 ng/mLactiveconfirmed F10.20S — Synthetic modern diagnosis anchored to his own published account of heavy drinking; the criteria, scores and amounts are synthetic and are not a claim about his real drinking.
Alcohol-associated fatty liver without advanced fibrosis (liver stiffness 7.2 kPa; steatosis on ultrasound); FIB-4 2.28 at intakeactiveconfirmed K70.0S — Synthetic finding of the ultrasound and elastography at the consultation; not a claim about his real liver.
Daily self-directed naproxen for knee and back pain for about two years, stopped at intake; acetaminophen in its placeresolvedconfirmed Z79.1S — Synthetic medication history; the joint pain is anchored to the documented rheumatism of 1914, which is not given a diagnosis.
Cigarette smoking, about ten a day; not ready to stop while he stops drinkingactiveconfirmed F17.210S — Synthetic tobacco use; a physician-author's suggestion of heavy tobacco use is recorded only as a retrospective claim.
Right ankle sprain (lateral ligaments, moderate), from stepping into a burrow while walking the pasture; Ottawa ankle rules negative; healed in about four weeksresolvedconfirmed S93.401AS — Synthetic acute injury; not a historical claim.

Results

DateMeasureValueUnitReference rangeFlagProvenance
1915-08-04Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
1915-08-04Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
1915-08-04Carbon dioxide, total [Moles/volume] in Serum or Plasma22mmol/L22-29 mmol/LNormalS
1915-08-04Urea nitrogen [Mass/volume] in Serum or Plasma28mg/dL7-20 mg/dLHighS
1915-08-04Creatinine [Mass/volume] in Serum or Plasma1.98mg/dL0.74-1.35 mg/dLHighS
1915-08-04Glucose [Mass/volume] in Serum or Plasma94mg/dL70-99 mg/dLNormalS
1915-08-04Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1910)/1.73 sq M43mL/min/{1.73_m2}45 to 59 is G3a; 30 to 44 is G3bLowS
1915-08-04Albumin/Creatinine [Mass Ratio] in Urine240mg/gBelow 30 mg/g A1; 30 to 300 A2; above 300 A3HighS
1915-08-04Urate [Mass/volume] in Serum or Plasma8.4mg/dL4-8 mg/dLHighS
1915-08-04Calcium [Mass/volume] in Serum or Plasma9.2mg/dL8.6-10.3 mg/dLNormalS
1915-08-04Phosphate [Mass/volume] in Serum or Plasma3.8mg/dL2.5-4.5 mg/dLNormalS
1915-08-04Parathyrin.intact [Mass/volume] in Serum or Plasma74pg/mL15-65 pg/mLHighS
1915-08-04Hemoglobin [Mass/volume] in Blood13.6g/dL13-17 g/dLNormalS
1915-08-04MCV [Entitic mean volume] in Red Blood Cells by Automated count101fL80-100 fLHighS
1915-08-04Platelets [#/volume] in Blood by Automated count18210*3/uL150-400 10*3/uLNormalS
1915-08-04Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma68U/L10-40 U/LHighS
1915-08-04Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma41U/L9-46 U/LNormalS
1915-08-04Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma186U/L8-61 U/LHighS
1915-08-04Albumin [Mass/volume] in Serum or Plasma4.1g/dL3.5-5 g/dLNormalS
1915-08-04Bilirubin.total [Mass/volume] in Serum or Plasma0.9mg/dL0.2-1.2 mg/dLNormalS
1915-08-04INR in Platelet poor plasma by Coagulation assay1{INR}0.9-1.1NormalS
1915-08-04Phosphatidylethanol [Mass/volume] in Blood410ng/mLBelow 20 ng/mL abstinence or light drinking; above 200 heavy drinkingHighS
1915-08-04Hemoglobin A1c/Hemoglobin.total in Blood5.4%<=5.6%NormalS
1915-08-04Cholesterol [Mass/volume] in Serum or Plasma214mg/dL<=199 mg/dLHighS
1915-08-04Cholesterol in HDL [Mass/volume] in Serum or Plasma58mg/dL>=40 mg/dLNormalS
1915-08-04Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation128mg/dL<=129 mg/dLNormalS
1915-08-04Triglyceride [Mass/volume] in Serum or Plasma140mg/dL<=149 mg/dLNormalS
1915-08-04Total score [AUDIT]27{score}S
1915-08-04Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]9{score}S
1915-08-04Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]7{score}S
1915-08-18Potassium [Moles/volume] in Serum or Plasma4.9mmol/L3.5-5.1 mmol/LNormalS
1915-08-18Creatinine [Mass/volume] in Serum or Plasma2.04mg/dL0.74-1.35 mg/dLHighS
1915-08-18Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1910)/1.73 sq M42mL/min/{1.73_m2}45 to 59 is G3a; 30 to 44 is G3bLowS
1915-08-18Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma49U/L10-40 U/LHighS
1915-08-18Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma36U/L9-46 U/LNormalS
1915-08-18Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma141U/L8-61 U/LHighS
1915-09-15Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
1915-09-15Potassium [Moles/volume] in Serum or Plasma4.8mmol/L3.5-5.1 mmol/LNormalS
1915-09-15Carbon dioxide, total [Moles/volume] in Serum or Plasma23mmol/L22-29 mmol/LNormalS
1915-09-15Creatinine [Mass/volume] in Serum or Plasma1.96mg/dL0.74-1.35 mg/dLHighS
1915-09-15Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1910)/1.73 sq M44mL/min/{1.73_m2}45 to 59 is G3a; 30 to 44 is G3bLowS
1915-09-15Albumin/Creatinine [Mass Ratio] in Urine128mg/gBelow 30 mg/g A1; 30 to 300 A2; above 300 A3HighS
1915-09-15Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma34U/L10-40 U/LNormalS
1915-09-15Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma29U/L9-46 U/LNormalS
1915-09-15Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma82U/L8-61 U/LHighS
1915-09-15Phosphatidylethanol [Mass/volume] in Blood36ng/mLBelow 20 ng/mL abstinence or light drinking; above 200 heavy drinkingHighS
1915-09-1525-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma24ng/mLBelow 20 ng/mL deficient; 20 to 29 insufficientLowS
1915-09-15Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
1915-09-29Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
1915-10-13Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
1915-10-13Potassium [Moles/volume] in Serum or Plasma5mmol/L3.5-5.1 mmol/LNormalS
1915-10-13Carbon dioxide, total [Moles/volume] in Serum or Plasma23mmol/L22-29 mmol/LNormalS
1915-10-13Creatinine [Mass/volume] in Serum or Plasma1.95mg/dL0.74-1.35 mg/dLHighS
1915-10-13Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1910)/1.73 sq M44mL/min/{1.73_m2}45 to 59 is G3a; 30 to 44 is G3bLowS
1915-10-13Phosphatidylethanol [Mass/volume] in Blood8ng/mLBelow 20 ng/mL abstinence or light drinking; above 200 heavy drinkingNormalS
1915-10-27Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
1915-10-27Potassium [Moles/volume] in Serum or Plasma4.7mmol/L3.5-5.1 mmol/LNormalS
1915-10-27Carbon dioxide, total [Moles/volume] in Serum or Plasma23mmol/L22-29 mmol/LNormalS
1915-10-27Urea nitrogen [Mass/volume] in Serum or Plasma24mg/dL7-20 mg/dLHighS
1915-10-27Creatinine [Mass/volume] in Serum or Plasma2.13mg/dL0.74-1.35 mg/dLHighS
1915-10-27Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1910)/1.73 sq M40mL/min/{1.73_m2}45 to 59 is G3a; 30 to 44 is G3bLowS
1915-10-27Albumin/Creatinine [Mass Ratio] in Urine96mg/gBelow 30 mg/g A1; 30 to 300 A2; above 300 A3HighS
1915-10-27Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma29U/L10-40 U/LNormalS
1915-10-27Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma26U/L9-46 U/LNormalS
1915-10-27Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma54U/L8-61 U/LNormalS
1915-10-27MCV [Entitic mean volume] in Red Blood Cells by Automated count96fL80-100 fLNormalS
1915-10-27Phosphatidylethanol [Mass/volume] in Blood6ng/mLBelow 20 ng/mL abstinence or light drinking; above 200 heavy drinkingNormalS
1915-10-27Total score [AUDIT]9{score}S
1915-10-27Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
1915-10-27Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]4{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
1915-08-04Body height173cmS
1915-08-04Body weight84.2kgS
1915-08-04Body mass index (BMI) [Ratio]28.1kg/m2S
1915-08-04Systolic blood pressure158mm[Hg]S
1915-08-04Diastolic blood pressure98mm[Hg]S
1915-08-04Heart rate92/minS
1915-08-04Respiratory rate16/minS
1915-08-04Body temperature36.8CelS
1915-08-04Oxygen saturation in Arterial blood by Pulse oximetry97%S
1915-08-18Body height173cmS
1915-08-18Body weight83.6kgS
1915-08-18Body mass index (BMI) [Ratio]27.9kg/m2S
1915-08-18Systolic blood pressure146mm[Hg]S
1915-08-18Diastolic blood pressure92mm[Hg]S
1915-08-18Heart rate84/minS
1915-08-18Respiratory rate16/minS
1915-08-18Body temperature36.6CelS
1915-08-18Oxygen saturation in Arterial blood by Pulse oximetry98%S
1915-09-15Body height173cmS
1915-09-15Body weight82.6kgS
1915-09-15Body mass index (BMI) [Ratio]27.6kg/m2S
1915-09-15Systolic blood pressure138mm[Hg]S
1915-09-15Diastolic blood pressure86mm[Hg]S
1915-09-15Heart rate78/minS
1915-09-15Respiratory rate14/minS
1915-09-15Body temperature36.6CelS
1915-09-15Oxygen saturation in Arterial blood by Pulse oximetry98%S
1915-10-13Body height173cmS
1915-10-13Body weight81.4kgS
1915-10-13Body mass index (BMI) [Ratio]27.2kg/m2S
1915-10-13Systolic blood pressure126mm[Hg]S
1915-10-13Diastolic blood pressure80mm[Hg]S
1915-10-13Heart rate72/minS
1915-10-13Respiratory rate14/minS
1915-10-13Body temperature36.6CelS
1915-10-13Oxygen saturation in Arterial blood by Pulse oximetry98%S
1915-10-27Body height173cmS
1915-10-27Body weight80.9kgS
1915-10-27Body mass index (BMI) [Ratio]27kg/m2S
1915-10-27Systolic blood pressure122mm[Hg]S
1915-10-27Diastolic blood pressure78mm[Hg]S
1915-10-27Heart rate70/minS
1915-10-27Respiratory rate14/minS
1915-10-27Body temperature36.6CelS
1915-10-27Oxygen saturation in Arterial blood by Pulse oximetry98%S
1915-09-29Body height173cmS
1915-09-29Body weight82kgS
1915-09-29Body mass index (BMI) [Ratio]27.4kg/m2S
1915-09-29Systolic blood pressure130mm[Hg]S
1915-09-29Diastolic blood pressure82mm[Hg]S
1915-09-29Heart rate74/minS
1915-09-29Respiratory rate14/minS
1915-09-29Body temperature36.6CelS
1915-09-29Oxygen saturation in Arterial blood by Pulse oximetry98%S
1915-09-01Body height173cmS
1915-09-01Body weight83.2kgS
1915-09-01Body mass index (BMI) [Ratio]27.8kg/m2S
1915-09-01Systolic blood pressure142mm[Hg]S
1915-09-01Diastolic blood pressure88mm[Hg]S
1915-09-01Heart rate88/minS
1915-09-01Respiratory rate16/minS
1915-09-01Body temperature36.7CelS
1915-09-01Oxygen saturation in Arterial blood by Pulse oximetry98%S

Encounters

DatePurposeStatusProvenance
1915-08-04Establishing care for tiredness and ankle swelling, with high blood pressure and abnormal kidney tests, and heavy drinking found at the visit: kidney, liver and alcohol tests, AUDIT and DSM-5-TR assessment, withdrawal planning, mood and safety, his writing schedule, and a nephrology consultationfinishedS
1915-08-18Two-week review after stopping alcohol and starting losartan, seen the same day by nephrology: kidney staging and cause, ultrasound and elastography, blood pressure target, medicine for alcohol use disorder, and pain relieffinishedS
1915-09-15Six-week review: drinking and PEth, blood pressure, potassium and creatinine, urine albumin, liver tests, mood and safetyfinishedS
1915-10-13Ten-week review: abstinence, potassium and creatinine after the losartan increase, and the SGLT2 inhibitorfinishedS
1915-10-27Twelve-week review: kidney function after the SGLT2 inhibitor, urine albumin, liver tests, AUDIT, mood, safety and the plan aheadfinishedS
1915-09-29Periodic adult preventive visitfinishedS
1915-09-01Same-day sick visit for a right ankle sprainfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Kidneys and blood pressure: creatinine with eGFR (CKD-EPI 1910), urine albumin-to-creatinine ratio and urinalysis with microscopy, electrolytes and bicarbonate, uric acid, calcium, phosphate and PTH, blood count, HbA1c and a lipid panel once; the earlier insurance creatinine obtained; ultrasound of the kidneys and liver; standardized office blood pressure at every visit and home readingscompletedGL-KDIGO-CKD-2024, GL-KDIGO-BP-2021, GL-CMID-2026S
Nephrology consultation to confirm the stage and cause of the kidney disease and advise on blood pressure, an SGLT2 inhibitor, medicines for alcohol use disorder at his kidney function, and pain reliefcompletedGL-KDIGO-CKD-2024, GL-KDIGO-BP-2021S
Losartan 50 mg daily from intake, raised to the maximum tolerated dose, with potassium and creatinine two to four weeks after each start or change, accepting a rise in creatinine of up to 30 percent; less saltcompletedGL-KDIGO-BP-2021, GL-AHA-HTN-2025, GL-CMID-2026S
Alcohol: AUDIT, DSM-5-TR criteria and PEth with consent; liver tests and FIB-4; a withdrawal-risk score (PAWSS) and outpatient withdrawal with a five-day chlordiazepoxide taper, daily telephone checks and thiamine; addiction-focused counseling with the clinic's addiction medicine team each week and mutual-help meetings if he wishes; PEth and liver tests at follow-upcompletedGL-APA-AUD-2018, GL-SUD-2021, GL-ASAM-AWM-2020, GL-AASLD-NIT-2025S
Medicine for alcohol use disorder: naltrexone 50 mg daily, which needs no dose change at his kidney function, with liver tests and a wallet card about opioid blockade; acamprosate not chosen because it needs a lower dose at his creatinine clearance and is avoided below 30 mL/min, and he could not reliably take it three times a daycompletedGL-APA-AUD-2018, GL-SUD-2021, GL-KDIGO-CKD-2024S
Liver: ultrasound and vibration-controlled transient elastography for an indeterminate FIB-4; abstinence as the treatmentcompletedGL-AASLD-ALD-2019, GL-AASLD-NIT-2025S
SGLT2 inhibitor (dapagliflozin 10 mg daily) once he has been abstinent for some weeks and is eating regularly, because heavy drinking and fasting raise the risk of ketoacidosis; held on days he cannot eat or drink, with potassium and creatinine two to four weeks after starting, accepting an early fall in eGFRcompletedGL-KDIGO-CKD-2024, GL-CMID-2026S
Pain and medicine safety: no naproxen, ibuprofen or other oral anti-inflammatory medicines; acetaminophen up to 2,000 mg a day; no opioids or tramadol with kidney disease and in early recovery, and none at all if naltrexone is started; any new medicine checked for kidney dosingcompletedGL-KDIGO-CKD-2024, GL-CMID-2026S
Safety: a structured safety assessment, firearms locked with ammunition apart, small supplies of withdrawal medicine, a written safety plan, the 988 Suicide & Crisis Lifeline, and safety review at every visitcompletedGL-SUICIDE-2024, GL-USPSTF-DEP-2023S
Work and recovery: keep the morning writing hours from nine to eleven; replace the late-morning drink with a swim or a ride; no alcohol kept in the writing room; PHQ-9 and GAD-7 at intake and follow-upcompletedGL-SUD-2021, GL-USPSTF-DEP-2023S
Tobacco: advice to stop, with nicotine replacement or varenicline offered when he is readycompletedGL-USPSTF-TOB-2021S

Goals

GoalTargetStatusOutcomeProvenance
Find out how much kidney function is lost, how long it has been so, and why1915-08-18completedChronic kidney disease G3b A2 from hypertension with naproxen contributing; no stones, obstruction or glomerular disease suspectedS
Stop drinking safely, and stay stopped1916-02-02activeWithdrawal completed without complications; one evening of drinking at four weeks; abstinent since, with PEth 8 and then 6 ng/mLS
Blood pressure below 120 systolic by standardized office measurement if tolerated, and at least below 130/801916-02-02active158/98 to 122/78 at twelve weeks on losartan 100 mgS
Urine albumin down by at least 30 percent1915-10-27completed240 to 96 mg/g on losartan and then dapagliflozinS
No anti-inflammatory pain medicines, and pain controlled1915-10-27completedNo naproxen since intake; acetaminophen and topical treatment only, including for an ankle sprainS
Keep the morning writing hours1915-10-27completedWrote every morning through the twelve weeks except the two days of the worst withdrawalS

Functional Status

Mental Status

Structured synthetic safety assessment on 1915-08-04: current ideation absent, intent absent, plan absent. Outpatient care with close follow-up. Risk factors reviewed without detail: severe alcohol use disorder, a new chronic illness, financial pressure, mild depressive and anxiety symptoms, and firearms on the ranch. He agreed that the rifle and shotgun will be kept locked in the ranch office safe with the ammunition stored apart, and that he will not handle them after drinking. Chlordiazepoxide is dispensed for five days only, with a daily telephone check. A written safety plan was made with him, and the 988 Suicide & Crisis Lifeline (call or text 988) and the clinic's number were written on a card he carries. Safety is reviewed at every visit [S]